Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716132 | 0.69 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL10544476 | 0.67 | CHRM2 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL10545842 | 0.64 | CHRM2 (0.34) | CHRM2CHRM1CHRM3 | |
| SCHEMBL405799 | 0.64 | SMN1; SMN2 (0.38) | MAPT | |
| SCHEMBL406203 | 0.64 | SLC6A2 (0.36) | — | |
| SCHEMBL11379036 | 0.61 | CHRM2 (0.34) | CHRM2CHRM1CHRM3 | |
| SCHEMBL11388338 | 0.60 | CHRM2 (0.33) | MAPTCHRM2CHRM1CHRM3 | |
| SCHEMBL27569810 | 0.59 | CES2 (0.39) | CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL5347348 | 0.59 | SMN1; SMN2 (0.40) | MAPT | |
| SCHEMBL11054238 | 0.58 | ALDH1A1 (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638938-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECH INC (US) | 2017-04-12 | — | — | EP | claimed |
| US-8124643-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-8039504-B2 | heating a mixture of anti-tricyclo[3.2.2.0]non-6-ene-endo-8, endo-9-dicarboxylic acid anhydride, 4-(trifluoromethyl)benzhydrazide, and ethanol at reflux, concetrating and recrystallizing; 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide | SIGA TECHNOLOGIES, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-7737168-B2 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-06-15 | — | — | US | claimed |
| EP-1638938-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES INC (US) | 2008-09-17 | — | — | EP | claimed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | claimed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | claimed |
| EP-1638938-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | Siga Technologies, Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2004112718-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1638938-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECH INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9045418-B2 | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC., (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802714-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130345278-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20110009456-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | SIGA TECHNOLOGIES INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100227892-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | SIGA TECHNOLOGIES INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7737168-B2 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7687641-B2 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | MAPT 2375/4885CHRM2 4826/4885CHRM1 4820/4885 |
| US-20100227892-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | OTC, FAHD1, VAC14 | MAPT 2081/4885CHRM2 4818/4885CHRM1 4824/4885 |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | MAPT 2375/4885CHRM2 4826/4885CHRM1 4820/4885 |
| US-20110009456-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | OTC, FAHD1, VAC14 | MAPT 2081/4885CHRM2 4818/4885CHRM1 4824/4885 |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | MAPT 2081/4885CHRM2 4818/4885CHRM1 4824/4885 |
| US-20130345278-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | MAPT 2081/4885CHRM2 4818/4885CHRM1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.